All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: HBM9161
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: BlackRock Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 17, 2020
Details:
Net proceeds to be used in development of company's three anchor products: Batoclimab, tanfanercept, and HBM4003, to fund ongoing and planned clinical trials, and potential commercialization of other drug candidates in the Company’s pipeline.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Leniolisib
Therapeutic Area: Immunology Product Name: CDZ173
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Leniolisib is a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor with immunomodulating and potentially anti-neoplastic activities. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate (PIP3).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nipocalimab
Therapeutic Area: Immunology Product Name: M281
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $6,500.0 million Upfront Cash: $6,500.0 million
Deal Type: Acquisition October 01, 2020
Details:
Johnson & Johnson's pipeline gains a new class of drugs. Momenta’s FcRn inhibitor, nipocalimab, has the potential to transform treatment of autoantibody-driven autoimmune diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nipocalimab
Therapeutic Area: Immunology Product Name: M281
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $6,500.0 million Upfront Cash: $6,500.0 million
Deal Type: Acquisition August 19, 2020
Details:
This acquisition gives Johnson & Johnson a major entry point into a new class of drugs. Momenta’s FcRn inhibitor, nipocalimab, has the potential to transform treatment of autoantibody-driven autoimmune diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
National Medical Products Administration (NMPA, China) approved IND application for HBM9161, a full-human antibody targeting neonatal Fc receptor (FcRn), to conduct a Phase 2/3 clinical trial in patients with Graves‘ ophthalmopathy (GO).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2020
Details:
Anti-FcRn antibody has potential to become portfolio-in-a-product; ITP trial is the first of several to study safety and efficacy in autoimmune disorders.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nipocalimab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Details:
Company is in active communication with clinical sites to be sure patients enrolled in studies have uninterrupted access to company's investigational drugs.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
